Cover Image
市場調查報告書

燒燙傷:開發中產品分析

Burns - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213115
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
燒燙傷:開發中產品分析 Burns - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 106 Pages
簡介

所謂燒燙傷 (燙傷,燒傷) 是指由於熱能和化學藥品,電力,日光,放射性核能等造成人體組織的損傷。主要的症狀有疼痛 (燒燙傷程度愈大疼痛也愈強) ,及皮膚的發炎·腫包,水痘,炭化,變色 (變黑) 等。主要的治療方法有抗生素和止痛藥等。

本報告提供全球各國治療燒燙傷所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

燒燙傷概要

治療藥的開發

  • 燒燙傷開發中產品:概要
  • 燒燙傷開發中產品:比較分析

各企業開發中的的燒燙傷治療藥

大學/研究機關研究中的燒燙傷治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

燒燙傷治療藥:開發中的產品一覽 (各企業)

燒燙傷治療藥:研究中的產品一覽 (各大學/研究機關)

燒燙傷開發治療藥的企業

  • Adocia
  • AlgiPharma AS
  • Amarantus Bioscience Holdings, Inc.
  • American Gene Technologies International Inc.
  • Biogenomics Limited
  • CytoTools AG
  • Destiny Pharma Limited
  • Lakewood-Amedex Inc
  • Madam Therapeutics B.V.
  • MediWound Ltd.
  • Mitochon Pharmaceuticals, Inc.
  • Phosphagenics Limited
  • Se-cure Pharmaceuticals Ltd.
  • Sinclair Pharma Plc
  • Stratatech Corporation
  • Tissue Therapies Limited
  • USV Pvt Ltd

燒燙傷:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

燒燙傷治療藥:開發暫停的產品

燒燙傷治療藥:開發中止的產品

燒燙傷相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8404IDB

Summary

Global Markets Direct's, 'Burns - Pipeline Review, H2 2016', provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Burns
  • The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Burns therapeutics and enlists all their major and minor projects
  • The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Burns

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Burns
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burns Overview
  • Therapeutics Development
    • Pipeline Products for Burns - Overview
    • Pipeline Products for Burns - Comparative Analysis
  • Burns - Therapeutics under Development by Companies
  • Burns - Therapeutics under Investigation by Universities/Institutes
  • Burns - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Burns - Products under Development by Companies
  • Burns - Products under Investigation by Universities/Institutes
  • Burns - Companies Involved in Therapeutics Development
    • Adocia
    • AlgiPharma AS
    • Amarantus Bioscience Holdings, Inc.
    • American Gene Technologies International Inc.
    • Biogenomics Limited
    • CytoTools AG
    • Destiny Pharma Limited
    • Lakewood-Amedex Inc
    • Madam Therapeutics B.V.
    • MediWound Ltd.
    • Mitochon Pharmaceuticals, Inc.
    • Phosphagenics Limited
    • Se-cure Pharmaceuticals Ltd.
    • Sinclair Pharma Plc
    • Stratatech Corporation
    • Tissue Therapies Limited
    • USV Pvt Ltd
  • Burns - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A-3APO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • albumin (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALLO-ASC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biochaperone PDGF-BB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bromelains - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Dermatology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epidermal growth factor biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMSP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target TNF-alpha for Burns, Inflammation and Wounds - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-2000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligomer G for Wounds And Burns - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PEP-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • silver sulfadiazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Burn - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium hypochlorite - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VF-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XF-70 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burns - Dormant Projects
  • Burns - Discontinued Products
  • Burns - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: MediWound's NexoBrid Receives Reimbursement in Italy
      • May 19, 2016: MediWound's NexoBrid Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting
      • May 02, 2016: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
      • Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized
      • Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
      • Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
      • Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania
      • Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid
      • Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.
      • Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress
      • Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress
      • Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting
      • Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting
      • Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns
      • Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burns, H2 2016
  • Number of Products under Development for Burns - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Burns - Pipeline by Adocia, H2 2016
  • Burns - Pipeline by AlgiPharma AS, H2 2016
  • Burns - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Burns - Pipeline by American Gene Technologies International Inc., H2 2016
  • Burns - Pipeline by Biogenomics Limited, H2 2016
  • Burns - Pipeline by CytoTools AG, H2 2016
  • Burns - Pipeline by Destiny Pharma Limited, H2 2016
  • Burns - Pipeline by Lakewood-Amedex Inc, H2 2016
  • Burns - Pipeline by Madam Therapeutics B.V., H2 2016
  • Burns - Pipeline by MediWound Ltd., H2 2016
  • Burns - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Burns - Pipeline by Phosphagenics Limited, H2 2016
  • Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H2 2016
  • Burns - Pipeline by Sinclair Pharma Plc, H2 2016
  • Burns - Pipeline by Stratatech Corporation, H2 2016
  • Burns - Pipeline by Tissue Therapies Limited, H2 2016
  • Burns - Pipeline by USV Pvt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Burns - Dormant Projects, H2 2016
  • Burns - Dormant Projects (Contd..1), H2 2016
  • Burns - Dormant Projects (Contd..2), H2 2016
  • Burns - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Burns, H2 2016
  • Number of Products under Development for Burns - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top